Expanding Pharmaceutical Industry to Lead Growth in the Global Transient Ischemic Attack Market

Transient Ischemic Attack Market Analysis

Transient ischemic attack is caused as a result of the loss of blood flow to the brain, retina, or the spinal cord which has symptoms similar to that of a stroke. The duration for which the symptoms last is only a few minutes, so no permanent damage is caused and is often called a mini stroke. As per the analysis of Market Research Future (MRFR), the global transient ischemic attack market is set to expand by valuation at a CAGR of 6.08% over the forecast period of 2017-2023. 

The growing burden of neurological disorders, especially transient ischemic attack, has resulted in an upshot in demand for medical diagnosis and treatment services. The American Heart Association and American Stroke Association Stroke Council suggest undergoing head imaging within 24 hours of onset of symptoms of transient ischemic attack, preferably MRI.

The rapidly expanding pharmaceutical industry has been a plus for the growth of the global transient ischemic attack market. Drugs which were previously not available are now being marketed extensively by pharmaceutical companies to cater to the requirements of the patient pool across the globe. Drugs such as Plavix, Alteplase, Activase, Aggrenox, and others are increasingly manufactured which has created an opportunity for the global transient ischemic attack market to expand successfully. 

Minimally-invasive surgeries have emerged as the most common line of treatment for various cardiac diseases. They have demonstrated their efficiency in the treatment of transient ischemic attack and are associated with the advantages of rapid recovery and less post-surgical pain. This has spurred the preference of this surgery as a treatment option for transient ischemic attack, which has propelled the growth of the market.

Avail Free Sample Copy at https://www.marketresearchfuture.com/sample_request/5025

Other factors which have boosted the growth of the market include the increase in the numbers of the elderly, high healthcare expenditure of nations, and growing government support for R&D activities. On the contrary, the growth of the market might be hindered by the risks associated with surgical techniques and high costs associated with the treatment of the disease.

Transient Ischemic Attack Market Segmentation

The global transient ischemic attack market has been segmented based on diagnosis, treatment, age group, and end user. 

By diagnosis, the global transient ischemic attack market has been segmented into imaging technique and others. 

By treatment, the global transient ischemic attack market has been segmented into drugs and surgeries. 

By age group, the global transient ischemic attack market has been segmented into 60+ years, 41-60 years, 19-40 years, and 0-18 years. 

By end user, the global transient ischemic attack market has been segmented into hospitals & clinics, research laboratories, diagnostic centers, and others. 

Regional Analysis

By region, the global transient ischemic attack market has been segmented into North America, South America, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). 

North America and South America collectively account for more than one-third share of the market and the same growth trend are expected to continue over the forecast period. The Americas market is driven by factors such as the growing prevalence of neurological disorders, increasing government support for R&D and high healthcare expenditure. Additionally, the presence of major players in the region acts a plus for the growth of the market. 

Europe is the second largest market driven by the availability of funds for research and development activities. 

APAC is expected to showcase the highest growth rate over the forecast period. Factors such as expanding healthcare expenditure, and growing awareness in the region. 

Transient Ischemic Attack Market Competitive Landscape

The key players in the global transient ischemic attack market include Nihon Kohden Corporation (Japan), LivaNova PLC (U.K), Siemens AG (Germany), Boston Scientific Corporation (US), Koninklijke Philips N.V. (Netherland), GE Healthcare (U.S.), Boston Scientific Corporation (Germany), ElectroCore Medical LLC (U.S.), Penumbra, Inc. (U.S.), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), Stryker Corporation (U.S.), Inspire Medical Systems, Inc.(U.S.), F. Hoffmann-La Roche AG (Switzerland), Pfizer Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), EnteroMedics Inc. (U.S.), Medtronic PLC (U.S.), Cyberonics, Inc. (US), Abbott Laboratories Inc. (U.S.), Hologic (U.S.), Sanofi (France), Electrical Geodesics Inc. (U.S.), Merck & Co., Inc. (U.S.), Esaote (Italy), Bayer AG (Germany), Masimo Corporation (U.S.), and Boehringer Ingelheim GmbH (Germany).

Browse Complete Report with TOC at https://www.marketresearchfuture.com/reports/transient-ischemic-attack-market-5025